• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PureTech Health plc - American Depositary Shares (NQ:PRTC)

18.53 -0.55 (-2.88%)
Streaming Delayed Price Updated: 1:44 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about PureTech Health plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
PureTech to Present at 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From PureTech Health plc
Via Business Wire
News headline image
PureTech Appoints Robert Lyne as Chief Executive Officer
December 18, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis
December 08, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
December 05, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech’s Founded Entity Gallop Oncology to Present New Data from Ongoing Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting
November 03, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
October 22, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
September 29, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo™ (SPT-320) in Healthy Volunteers
September 11, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Health plc – Half-Year Report
August 28, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
August 21, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Health: Notice of Half-Yearly Results
August 18, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
August 13, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
August 12, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo™ (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress
July 17, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Leadership Transition
July 16, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Board Change
July 08, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
June 26, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Health: Results of Annual General Meeting
June 16, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech to Present at the Jefferies Global Healthcare Conference
May 22, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
May 20, 2025
From PureTech
Via Business Wire
News headline image
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
May 09, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
May 01, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Announces Annual Results for Year Ended December 31, 2024
April 30, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Health: Notice of Results
April 23, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Appoints Peel Hunt as Joint UK Corporate Broker
April 09, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Health plc Statement Regarding Press Speculation
April 07, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair
March 11, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech to Present at the Leerink Partners Global Healthcare Conference
February 25, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
February 12, 2025
From PureTech Health plc
Via Business Wire
News headline image
PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
January 27, 2025
From PureTech Health plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap